China High Quality 22483-09-6 Factories – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We are commitment to offer you the aggressive price tag ,exceptional products and solutions high-quality, as well as fast delivery for 2-Iodo-1-P-Tolyl-Propan-1-One, D-Tartaric Acid, Cas 80-43-3, Now we have extensive goods source as well as price tag is our advantage. Welcome to inquire about our products and solutions.
China High Quality 22483-09-6 Factories – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality 22483-09-6 Factories –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

Innovation, quality and reliability are the core values of our company. These principles today more than ever form the basis of our success as an internationally active mid-size company for China High Quality 22483-09-6 Factories – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Surabaya, Honduras, Libya, Most problems between suppliers and clients are due to poor communication. Culturally, suppliers can be reluctant to question items they do not understand. We break down people barriers to ensure you get what you want to the level you expect, when you want it. Faster delivery time and the product you want is our Criterion .
  • High Quality, High Efficiency, Creative and Integrity, worth having long-term cooperation! Looking forward to the future cooperation!
    5 Stars By Lena from Lyon - 2017.11.29 11:09
    This supplier offers high quality but low price products, it is really a nice manufacturer and business partner.
    5 Stars By Florence from Ottawa - 2017.09.30 16:36
    Write your message here and send it to us

    Related Products